MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$129,861K
Net Income
$14,867K
Net Profit Margin
11.45%
EPS
$0.11
Unit: Thousand (K) dollars
Revenue Breakdown
Selling, general and administrat...
Income (gain) from operations
Research and development compens...
Others
Revenue Breakdown
ZORYVEFoam
ZORYVECream0.3
ZORYVECream0.15
ZORYVECream0.05
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
129,861
105,398
129,503
99,219
Cost of sales
10,939
9,784
11,688
8,685
Research and development
20,355
30,627
20,451
19,604
Selling, general and administrative
82,138
74,076
78,977
62,404
Total operating expenses
113,432
114,487
111,116
90,693
Income (gain) from operations
16,429
-9,089
18,387
8,526
Interest income
2,279
2,275
8,897
-
Interest expense
3,406
4,368
3,001
3,071
Other income (expense), net
-157
-20
-6,418
2,035
Total other income (expense)
-1,284
-
-
-
Income (gain) before income taxes
15,145
-11,202
17,865
7,490
Provision for income taxes
136
93
470
80
Segment and consolidated net income (gain)
15,009
-11,295
17,395
7,410
Unrealized gain (loss) on marketable securities
-96
-351
-42
68
Foreign currency translation adjustment
-46
-119
60
-95
Total other comprehensive income (gain)
-142
-470
18
-27
Comprehensive income (gain)
14,867
-11,765
17,413
7,383
Basic EPS
0.11
-0.09
0.136
0.06
Diluted EPS
0.11
-0.09
0.142
0.06
Basic Average Shares
130,522,000
129,365
128,279,138
127,623,000
Diluted Average Shares
135,898,000
129,365
123,017,138
132,885,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
Selling, general and
administrative
$82,008K
(18.80%↑ Y/Y)
Research and development
compensation and...
$11,366K
(16.23%↑ Y/Y)
Cost of sales
$10,376K
(49.75%↑ Y/Y)
Other segment
expenses
$6,295K
(14.27%↑ Y/Y)
Research and
development-Topical Roflumilast...
$1,983K
(-29.85%↓ Y/Y)
Research and
development-ARQ234Program Costs
$1,302K
Research and
development-Other Program Costs
$102K
Total operating
expenses
$113,432K
(18.02%↑ Y/Y)
Income (gain) from
operations
$16,429K
(212.44%↑ Y/Y)
Total revenues
$129,861K
(59.33%↑ Y/Y)
Income (gain) from
operations
$16,429K
(212.44%↑ Y/Y)
Total operating
expenses
$113,432K
(18.02%↑ Y/Y)
Income (gain) before
income taxes
$15,145K
(197.43%↑ Y/Y)
Total other income
(expense)
-$1,284K
Interest income
$2,279K
Selling, general and
administrative
$82,138K
(18.75%↑ Y/Y)
Research and development
$20,355K
(4.64%↑ Y/Y)
Cost of sales
$10,939K
(46.01%↑ Y/Y)
Segment and
consolidated net income...
$15,009K
(194.48%↑ Y/Y)
Provision for income taxes
$136K
(-60.23%↓ Y/Y)
Interest expense
$3,406K
(12.45%↑ Y/Y)
Other income
(expense), net
-$157K
(-107.49%↓ Y/Y)
Comprehensive income (gain)
$14,867K
(194.21%↑ Y/Y)
Total other
comprehensive income (gain)
-$142K
(-235.24%↓ Y/Y)
Unrealized gain (loss) on
marketable securities
-$96K
(-1.05%↓ Y/Y)
Foreign currency
translation adjustment
-$46K
(-123.00%↓ Y/Y)
Buy us a coffee
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)
logo-arcutis (1)-svg
Arcutis Biotherapeutics, Inc. (ARQT)